Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira), a cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Janssen’s Stelara) are the mainstays of treatment, followed by oral targeted therapies comprising Janus kinase (JAK) inhibitors (Pfizer’s Xeljanz / Xeljanz XR and AbbVie’s Rinvoq). However, later-to-market drugs, such as a sphingosine 1-phosphate receptor (S1P-R) modulators (BMS’s Zeposia and Pfizer’s Velsipity) and an IL-23 inhibitor (Eli Lilly’s Omvoh), are increasing the market competition among later-line targeted therapies. Moreover, the availability of infliximab biosimilars and adalimumab biosimilars in the United States will further impact market dynamics.
Questions answered
Markets covered: United States
Key companies: AbbVie, Janssen, Pfizer, Takeda, UCB, BMS
Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz / Xeljanz XR, Simponi, Zeposia, Rinvoq, aminosalicylates, immunosuppressants
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses